Akebia Therapeutics Future Growth
Future criteria checks 4/6
Akebia Therapeutics is forecast to grow earnings and revenue by 59.6% and 18% per annum respectively while EPS is expected to grow by 60.4% per annum.
Key information
59.6%
Earnings growth rate
60.4%
EPS growth rate
Biotechs earnings growth | 31.8% |
Revenue growth rate | 18.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 26 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 237 | 38 | N/A | N/A | 2 |
12/31/2025 | 164 | -71 | N/A | -67 | 3 |
12/31/2024 | 189 | -64 | N/A | -29 | 3 |
12/31/2023 | 195 | -52 | -23 | -23 | N/A |
9/30/2023 | 194 | -59 | -76 | -76 | N/A |
6/30/2023 | 201 | -98 | -35 | -35 | N/A |
3/31/2023 | 271 | -56 | -69 | -69 | N/A |
12/31/2022 | 292 | -94 | -73 | -73 | N/A |
9/30/2022 | 294 | -158 | -81 | -81 | N/A |
6/30/2022 | 294 | -163 | -171 | -171 | N/A |
3/31/2022 | 221 | -276 | -204 | -204 | N/A |
12/31/2021 | 212 | -282 | -253 | -253 | N/A |
9/30/2021 | 211 | -299 | -221 | -221 | N/A |
6/30/2021 | 222 | -300 | -192 | -192 | N/A |
3/31/2021 | 259 | -392 | -92 | -92 | N/A |
12/31/2020 | 295 | -385 | -111 | -110 | N/A |
9/30/2020 | 308 | -391 | -172 | -172 | N/A |
6/30/2020 | 340 | -386 | -136 | -134 | N/A |
3/31/2020 | 351 | -268 | -214 | -209 | N/A |
12/31/2019 | 335 | -280 | -264 | -257 | N/A |
9/30/2019 | 325 | -245 | -246 | -239 | N/A |
6/30/2019 | 286 | -217 | -267 | -262 | N/A |
3/31/2019 | 234 | -193 | -218 | -215 | N/A |
12/31/2018 | 208 | -144 | -99 | -97 | N/A |
9/30/2018 | 238 | -68 | -41 | -40 | N/A |
6/30/2018 | 227 | -65 | -84 | -82 | N/A |
3/31/2018 | 206 | -53 | -68 | -67 | N/A |
12/31/2017 | 181 | -74 | -58 | -56 | N/A |
9/30/2017 | 92 | -127 | N/A | 56 | N/A |
6/30/2017 | 51 | -140 | N/A | 82 | N/A |
3/31/2017 | 22 | -154 | N/A | 31 | N/A |
12/31/2016 | 2 | -136 | N/A | 58 | N/A |
9/30/2016 | N/A | -118 | N/A | -61 | N/A |
6/30/2016 | N/A | -101 | N/A | -41 | N/A |
3/31/2016 | N/A | -76 | N/A | -27 | N/A |
12/31/2015 | N/A | -61 | N/A | -52 | N/A |
9/30/2015 | N/A | -51 | N/A | -39 | N/A |
6/30/2015 | N/A | -41 | N/A | -35 | N/A |
3/31/2015 | N/A | -38 | N/A | -30 | N/A |
12/31/2014 | N/A | -124 | N/A | -27 | N/A |
9/30/2014 | N/A | -123 | N/A | -23 | N/A |
6/30/2014 | N/A | -120 | N/A | -21 | N/A |
3/31/2014 | N/A | -164 | N/A | -16 | N/A |
12/31/2013 | N/A | -69 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AX9 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).
Earnings vs Market: AX9 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AX9 is expected to become profitable in the next 3 years.
Revenue vs Market: AX9's revenue (18% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: AX9's revenue (18% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AX9's Return on Equity is forecast to be high in 3 years time